Dan Vogl, MD, MSCE, reviews studies from ASH 2017 with a focus on recent advances in the treatment of relapsed multiple myeloma, including the triplet combination Pom/Cyclo/Dex, the IgG1k monoclonal antibody daratumumab, venetoclax, a Bcl-2 inhibitor, and the recently introduced nelfinavir, a protease inhibitor, and venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor. Dr. Vogl also discusses enrolling trials at the Abramson Cancer Center for patients with relapsed MM.
Recent Links:
Clinical Brief: Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
Dr. Vogl’s Profile
Connect on Doximity
Published
March 8, 2018
Created by
BROADCASTMED